Arteriocyte is now a part of Isto Biologics.

News + Views

Blog

ISTO Technologies to Present at OneMedPlace Finance Forum

Dec 21, 2007

St. Louis, MO – ISTO Technologies, Inc., a privately held orthobiologic company, announced today that it will participate in the OneMedPlace Finance Forum in San Francisco, CA from January 7-8, 2008. Mitchell Seyedin, Ph. D., President and CEO of ISTO, will present on Tuesday, January 8th at 11:00 a.m. Pacific Time, at the Sir Francis Drake Hotel at 450 Powell St. Information about the OneMedPlace Finance Forum may be found at www.onemedplace.com.

ISTO’s rich product pipeline includes DeNovo® ET, a tissue engineered cartilage implant in Phase I/II trials for resurfacing knee joints, NuQu™, a cartilage cell-based product in late-stage development for degenerated disc nucleus, and InQu®, a biomaterial for bone regeneration that has receive 510(k) clearance. ISTO’s innovative products are designed to address very large markets with unmet clinical needs.

Cartilage regeneration is often called the “holy grail” of the orthopedic industry because of its potential to restore function to damaged joints that otherwise have limited healing potential. Cartilage serves as a “shock absorber” protecting all joints, including spinal discs, from the wear and tear experienced during motion.

InQu represents a new class of biomaterial designed to offer a number of clinical advantages to surgeons and patients.

About ISTO Technologies, Inc.
ISTO Technologies, Inc. is developing and marketing clinical solutions for sports medicine, spinal therapy, and trauma. ISTO’s products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at www.istobiologics.com or contact the Company at 314-995-6049.

To top